Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
GamaMabs Pharma logo — Advancing the future of immuno-oncology with innovative mono...

GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments

Founded 2012 7 employees Series B Total: $18.10M Biotechnology, Health Care +1

General Information

Company Name GamaMabs Pharma
Founded Year 2012
Employees 7
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with GamaMabs Pharma. To contact GamaMabs Pharma, visit gamamabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GamaMabs Pharma compare?

A PDF of GamaMabs Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GamaMabs Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GamaMabs Pharma

GamaMabs Pharma is a biotechnology company focused on advancing the future of immuno-oncology with innovative monoclonal antibody treatments. The company's main program, GM102, targets the anti-Müllerian hormone receptor (AMHR2) in gynecological cancers and is currently in the phase Ia/Ib stage. GamaMabs utilizes EMABling® glyco-engineering technology to enhance tumor cell destruction by activating immune cells. Founded in June 2013 in Toulouse, France, GamaMabs collaborates with prestigious academic and private partners and employs professionals with extensive experience in preclinical and clinical development. The company leverages technologies created by LFB BIOTECHNOLOGIES, a French biopharma company, and has received a €15.00M Series B investment from IXO Private Equity, Alto Invest, InnoBio, Andera Partners, and IRDInov. GamaMabs' primary objective is to advance its monoclonal antibodies to the stage of Clinical Proof of Concept. With its focus on immuno-oncology and strategic partnerships, GamaMabs is poised to make significant strides in the biotechnology and healthcare industries.

Business keywords: immuno-oncology, monoclonal antibodies, cancer treatment, pharmaceuticals, clinical development, glyco-engineering, oncology research, collaborations, LFB BIOTECHNOLOGIES, EMABling® technology, HuMabFc technology, gynecological cancers, French biopharma, drug development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €15.00M 5
Andera Partner IXO Private Equity Alto Invest
Andera Partner, IXO Private Equity +3
15 Dec 2015
Series A €3.10M 1
Bpifrance
Bpifrance
30 Sep 2013
Non Equity Assistance Undisclosed 1
Eurasante
01 Jan 2012

GamaMabs Pharma Alternatives & Competitors

View All Alternatives
GamaMabs Pharma vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
GamaMabs Pharma vs
IOME BIO
IOME BIO France

Harnessing unique, proprietary microbiome insights to unlock the efficacy of immuno-oncology

4 employees
Biotechnology, Health Care
GamaMabs Pharma vs
BioWa, Inc.
BioWa, Inc. United States

PROVEN TECHNOLOGY. PROVEN TEAM. PROVEN COLLABORATORS.

9 employees
Biotechnology, Health Care
View all alternatives

FAQ About GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments
GamaMabs Pharma was founded in 2012.
GamaMabs Pharma operates in Biotechnology, Health Care and Health and Wellness. Its work centres on immuno-oncology, monoclonal antibodies, cancer treatment and pharmaceuticals.
GamaMabs Pharma has approximately 7 employees.
GamaMabs Pharma has completed 3 funding rounds, raising a total of $18.10M. The latest funding stage is Series B.
Top alternatives and competitors to GamaMabs Pharma include Farcast Biosciences, IOME BIO, BioWa, Inc., Apollomics, Vor Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GamaMabs Pharma and Farcast Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GamaMabs Pharma, https://bouncewatch.com/company/gamamabs-pharma, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes